2Q Sales Results

Net product revenues for Xtampza ER were $3.6 million for the 2017 Quarter

Way to go boys and girls, the sales force only costs us $30M per quarter.

Glad the commercial expert Joe will launch a new ad campaign, that should work!

 

stock still around $10/share. How many of us feel stupid for thinking would would get rich on these options?

 

Sit back. Relax. Collect the checks until the finally shutter this place for good.

 

This company and drug have a lot going for them and are well positioned in a highly restricted market. Don't count them out haters!

 

I love your optimism! Keep the faith my brotha!

 

Dont kid yourself. Collegium will be bought by this time next year, if not sooner. A real company with leaders who know what they're doing will scoop up our fantastic drug/technology as an addition to their pain portfolio--where it won't be the WHOLE portfolio.

 

I don't care- just as long as I have a job after a buyout, I am good

 

You think Our product would become an addition to somebody's pain portfolio ? Who would that be? A real company with leaders who know what they are doing (pretty much disqualifies any company I can think of) Purdue would be out, Endo is out, Pfizer ? As long as they give us a boatload of stock and best out options.

 

Nice to dream. But a pain product with less than 1% overall market share in a severely declining market that is being hung out to dry by every state and federal agency as well as formulary plan isnt exactly attractive.

 

The recruiter called me for an open position and I laughed. Who the hell would sign up for that?